ipilimumab,nivolumab
bms
['melsm', 'secombit', 'biomarker', 'melanoma']
#esmo22 | #secombit (sequential combo immuno and target therapy study): 4-years os data and preliminary biomarkers evaluation #melsm #melanoma #immunotherapy 
Latest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it